HRP20170110T1 - Monoklonska protutijela - Google Patents

Monoklonska protutijela Download PDF

Info

Publication number
HRP20170110T1
HRP20170110T1 HRP20170110TT HRP20170110T HRP20170110T1 HR P20170110 T1 HRP20170110 T1 HR P20170110T1 HR P20170110T T HRP20170110T T HR P20170110TT HR P20170110 T HRP20170110 T HR P20170110T HR P20170110 T1 HRP20170110 T1 HR P20170110T1
Authority
HR
Croatia
Prior art keywords
antibody
seq
variable region
fibrin
fibrinogen
Prior art date
Application number
HRP20170110TT
Other languages
English (en)
Croatian (hr)
Inventor
Katerina Akassoglou
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of HRP20170110T1 publication Critical patent/HRP20170110T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HRP20170110TT 2009-10-02 2010-09-30 Monoklonska protutijela HRP20170110T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24801409P 2009-10-02 2009-10-02
EP10821238.2A EP2483416B1 (en) 2009-10-02 2010-09-30 Monoclonal antibodies
PCT/US2010/050873 WO2011041518A1 (en) 2009-10-02 2010-09-30 Monoclonal antibodies

Publications (1)

Publication Number Publication Date
HRP20170110T1 true HRP20170110T1 (hr) 2017-03-24

Family

ID=43826649

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170110TT HRP20170110T1 (hr) 2009-10-02 2010-09-30 Monoklonska protutijela

Country Status (38)

Country Link
US (1) US8877195B2 (https=)
EP (1) EP2483416B1 (https=)
JP (1) JP5883389B2 (https=)
KR (1) KR101793221B1 (https=)
CN (1) CN102575277B (https=)
AR (1) AR078490A1 (https=)
AU (1) AU2010300559B2 (https=)
BR (1) BR112012008370B8 (https=)
CA (1) CA2774256C (https=)
CL (1) CL2012000788A1 (https=)
CO (1) CO6440561A2 (https=)
CR (1) CR20120127A (https=)
CY (1) CY1118540T1 (https=)
DK (1) DK2483416T3 (https=)
DO (1) DOP2012000089A (https=)
EA (1) EA023477B1 (https=)
ES (1) ES2614939T3 (https=)
GE (2) GEP20156214B (https=)
GT (1) GT201200096A (https=)
HR (1) HRP20170110T1 (https=)
HU (1) HUE031571T2 (https=)
IL (1) IL218621B (https=)
IN (1) IN2012DN03154A (https=)
LT (1) LT2483416T (https=)
MA (1) MA33704B1 (https=)
MX (1) MX2012003811A (https=)
MY (1) MY159359A (https=)
NZ (1) NZ598770A (https=)
PH (1) PH12012500551A1 (https=)
PL (1) PL2483416T3 (https=)
PT (1) PT2483416T (https=)
SI (1) SI2483416T1 (https=)
SM (2) SMT201700083T1 (https=)
TN (1) TN2012000149A1 (https=)
TW (1) TWI511741B (https=)
UA (1) UA108860C2 (https=)
WO (1) WO2011041518A1 (https=)
ZA (1) ZA201202227B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012162698A1 (en) 2011-05-26 2012-11-29 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of immune disorders
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2015106072A1 (en) 2014-01-11 2015-07-16 The J. David Gladstone Institutes Compositions and methods for in vitro assays of fibrin activity
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
JP7204132B2 (ja) * 2017-05-02 2023-01-16 国立研究開発法人国立がん研究センター プラスミンにより切断可能な抗不溶性フィブリン抗体と薬物とのコンジュゲート
CN115461462B (zh) * 2020-03-31 2024-11-29 国立研究开发法人国立癌症研究中心 与纤维蛋白结合的抗体及含有该抗体的药物组合物
US20240059761A1 (en) * 2020-12-16 2024-02-22 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Use of fibrin-targeting immunotherapy to reduce Coronavirus pathogenesis
WO2022159776A1 (en) * 2021-01-21 2022-07-28 Therini Bio, Inc. Antibodies which bind human fibrin and methods of use
AU2022294106A1 (en) * 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
AU2022293581A1 (en) * 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
EP4577566A1 (en) * 2022-08-22 2025-07-02 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Human anti-fibrin antibodies and uses thereof
EP4676499A2 (en) * 2023-03-10 2026-01-14 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Methods and compositions for cellular immunotherapy- fib4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031675A1 (en) * 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CN1961002B (zh) * 2004-05-27 2011-05-18 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
US7807645B2 (en) * 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment

Also Published As

Publication number Publication date
GEP20156214B (en) 2015-01-12
IL218621A0 (en) 2012-05-31
TW201116298A (en) 2011-05-16
KR20120094924A (ko) 2012-08-27
US20120183560A1 (en) 2012-07-19
IL218621B (en) 2018-07-31
CO6440561A2 (es) 2012-05-15
SI2483416T1 (sl) 2017-06-30
EA201270416A1 (ru) 2012-08-30
AR078490A1 (es) 2011-11-09
EA023477B1 (ru) 2016-06-30
CA2774256C (en) 2019-02-19
ES2614939T3 (es) 2017-06-02
MY159359A (en) 2016-12-30
ZA201202227B (en) 2014-11-26
LT2483416T (lt) 2017-04-25
MA33704B1 (fr) 2012-10-01
EP2483416A1 (en) 2012-08-08
BR112012008370B1 (pt) 2020-12-22
MX2012003811A (es) 2012-05-08
CN102575277A (zh) 2012-07-11
GEP20166458B (en) 2016-04-11
AU2010300559B2 (en) 2014-11-27
SMT201700083B (it) 2017-03-08
BR112012008370A2 (pt) 2016-11-29
HK1168871A1 (zh) 2013-01-11
CL2012000788A1 (es) 2012-09-14
CN102575277B (zh) 2015-07-29
DOP2012000089A (es) 2012-06-30
NZ598770A (en) 2014-01-31
CR20120127A (es) 2012-05-28
JP2013506425A (ja) 2013-02-28
UA108860C2 (xx) 2015-06-25
SMT201700083T1 (it) 2017-03-08
KR101793221B1 (ko) 2017-11-02
GT201200096A (es) 2014-12-23
EP2483416B1 (en) 2016-11-23
TN2012000149A1 (en) 2013-09-19
JP5883389B2 (ja) 2016-03-15
PL2483416T3 (pl) 2017-05-31
HUE031571T2 (en) 2017-07-28
DK2483416T3 (en) 2017-02-20
EP2483416A4 (en) 2013-06-26
US8877195B2 (en) 2014-11-04
WO2011041518A1 (en) 2011-04-07
PH12012500551A1 (en) 2016-03-11
CA2774256A1 (en) 2011-04-07
TWI511741B (zh) 2015-12-11
PT2483416T (pt) 2017-02-14
CY1118540T1 (el) 2017-07-12
AU2010300559A1 (en) 2012-04-05
IN2012DN03154A (https=) 2015-09-18
BR112012008370B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HRP20170110T1 (hr) Monoklonska protutijela
JP2013506425A5 (https=)
HRP20191999T1 (hr) Monoklonska protutijela anti-faktora xi i postupci njihove uporabe
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
HRP20211343T1 (hr) Protutijela protiv dkk-1
JP2010522141A5 (https=)
EA201370105A1 (ru) Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a)
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
EA201000809A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
HRP20110334T1 (hr) PROTUTIJELA SPECIFIČNA ZA TGF-ß1
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
UA109633C2 (uk) Антитіло людини проти тканинного фактора
HRP20160151T1 (hr) PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
HRP20161677T1 (hr) Pegilirani fab protiv amiloida beta
RU2012149227A (ru) Биологические материалы, относящиеся к her3
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
JP6587609B2 (ja) 強皮症治療のための抗ccl2及び抗loxl2併用療法
PE20071055A1 (es) Anticuerpos anti mn
RU2014108047A (ru) Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
AR069062A1 (es) Anticuerpo anti-hepcidina
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
RU2018117862A (ru) Новый полипептид с аффинностью к PD-L1
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus